Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab
Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.
Authors
- Emanuele Cozzani (ORCID: https://orcid.org/0000-0003-3108-4123)
- Ilaria Trave (ORCID: https://orcid.org/0000-0002-5469-4517)
- Ilaria Salvi (ORCID: https://orcid.org/0000-0003-0151-3126)
- Giorgio Battaglia (ORCID: https://orcid.org/0000-0003-3254-9447)
- Aurora Parodi (ORCID: https://orcid.org/0000-0002-6622-2226)
- Alice Vischi
Institutions
- Ospedale Policlinico San Martino (IT)
- University of Turin (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1080/09546634.2025.2495831
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00